$联合治疗(UTHR)$ IPF大利好。暴涨38%。我们跟踪的时候是80亿美刀。现在190亿刀。UTHR reported its Phase 3 TETON-2 trial of nebulized Tyvaso in idiopathic pulmonary fibrosis met the primary endpoint with a 95.6 mL FVC improvement at 52 weeks (p<0.0001), with significant benefi

$联合治疗(UTHR)$

IPF大利好。暴涨38%。我们跟踪的时候是80亿美刀。现在190亿刀。

UTHR reported its Phase 3 TETON-2 trial of nebulized Tyvaso in idiopathic pulmonary fibrosis met the primary endpoint with a 95.6 mL FVC improvement at 52 weeks (p<0.0001), with significant benefits across multiple secondary measures and a favorable safety profile.

变性人妈妈，40不惑，为PAH女儿等开始创业Biotech。传奇！#Seeking# #biotech#

发布于上海